In vitro activity: Pocapavir, formerly known as SCH-48973 and V-073, is a novel, potent, and selective antienterovirus agent that is under clinical investigation. Pocapavir acts as a capsid inhibitor by preventing virion uncoating upon entry into the cell. The patient was treated with the novel antiviral, pocapavir, in addition to a standard heart failure regimen. The dystrophic calcification persisted but the left ventricle remodeled significantly. This is the first reported use of pocapavir for this indication. Treatment with pocapavir was safe and significantly accelerated virus clearance. Emergence of resistant virus and transmission of virus were seen in the context of a clinical isolation facility.

Kinase Assay: Pocapavir belongs to a picornavirus antiviral mechanistic class called capsid inhibitors that block virus uncoating and viral RNA release into cells, which in turn prevents virus replication

Cell Assay: Pocapavir acts as a capsid inhibitor, preventing virion uncoating upon entry into the cell. Treatment with Pocapavir is safe and significantly accelerates virus clearance